Amgen (AMGN) Short term Debt (2010 - 2026)

Amgen's Short term Debt history runs 15 years deep, the most recent figure standing at $5.4 billion for Q1 2026.

• In Q1 2026, Short term Debt rose 61.43% year-over-year to $5.4 billion; the TTM figure through Mar 2026 stood at $5.4 billion (up 61.43% YoY), while the FY2025 annual figure was $4.6 billion, up 29.55% from the prior year.
• Short term Debt was $5.4 billion for Q1 2026 at Amgen, up from $4.6 billion in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $5.5 billion in Q2 2024 to a low of $817.0 million in Q2 2022.
• Historically, Short term Debt has averaged $2.7 billion across 5 years, with a median of $2.2 billion in 2023.
• Biggest YoY gain for Short term Debt was 1728.74% in 2022; the steepest drop was 81.11% in 2022.
• A 5-year view of Short term Debt shows it stood at $1.6 billion in 2022, then decreased by 9.3% to $1.4 billion in 2023, then soared by 146.02% to $3.6 billion in 2024, then increased by 29.55% to $4.6 billion in 2025, then climbed by 18.22% to $5.4 billion in 2026.
• The last three Short term Debt figures came in at $5.4 billion (Q1 2026), $4.6 billion (Q4 2025), and $2.2 billion (Q3 2025), per Business Quant data.